News
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.
Potential Positives. Kymera Therapeutics has successfully priced a public offering of $250.8 million, providing significant capital for further development and expansion of its pipeline.
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback